[Chemotherapy for prostate cancer].
Chemotherapy treatment for patients with prostate cancer has advanced considerably during the past decade. The first demonstration of the efficacy of palliative chemotherapy in patients with hormone-resistant prostate cancer was followed by FDA approval of mitoxantrone in this setting and by studies showing the usefulness of several different drugs in these patients. Docetaxel became the standard treatment for them. The development of new cytotoxic molecules and targeted therapies as well as the evaluation of the efficacy of docetaxel in earlier stages of prostate cancer, with many ongoing studies, are the current lines of research for improving management of these hormone-refractory patients.
Medioni
Jacques
J
Département de cancérologie médicale, Hôpital européen Georges Pompidou, F-75015 Paris, France. jacques.medioni@egp.aphp.fr <jacques.medioni@egp.aphp.fr>
Dionysopoulos
Dimitri
D
Banu
Eugéniu
E
Scotté
Floriant
F
Beuzeboc
Philippe
P
Oudard
Stéphane
S
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002117:Calcitriol / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm; D004961:Estramustine / Q000627:therapeutic use; D006801:Humans; D008297:Male; D020360:Neoadjuvant Therapy; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D043823:Taxoids / Q000494:pharmacology / Q000627:therapeutic use; D014815:Vitamins / Q000627:therapeutic use
D000970:Antineoplastic Agents; D043823:Taxoids; D014815:Vitamins; D000077143:Docetaxel; D004961:Estramustine; D002117:Calcitriol